Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Payables (2018 - 2025)

Historic Payables for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $12.2 million.

  • TransMedics' Payables fell 740.06% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year decrease of 740.06%. This contributed to the annual value of $10.3 million for FY2024, which is 1906.9% down from last year.
  • Per TransMedics' latest filing, its Payables stood at $12.2 million for Q3 2025, which was down 740.06% from $9.5 million recorded in Q2 2025.
  • TransMedics' Payables' 5-year high stood at $13.1 million during Q3 2024, with a 5-year trough of $1.3 million in Q1 2021.
  • In the last 5 years, TransMedics' Payables had a median value of $7.0 million in 2023 and averaged $7.5 million.
  • Over the last 5 years, TransMedics' Payables had its largest YoY gain of 45149.25% in 2021, and its largest YoY loss of 7347.74% in 2021.
  • TransMedics' Payables (Quarter) stood at $6.7 million in 2021, then plummeted by 49.77% to $3.3 million in 2022, then soared by 280.63% to $12.7 million in 2023, then decreased by 19.07% to $10.3 million in 2024, then rose by 18.17% to $12.2 million in 2025.
  • Its Payables was $12.2 million in Q3 2025, compared to $9.5 million in Q2 2025 and $10.6 million in Q1 2025.